Position in BHC
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$976
+$663 QoQ
Shares Held
198
+241.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#199
of 220 holders
Holding Since
Mar 2022
5 quarters on record
Voting authority
Sole 14%
Shared 0%
None 86%
Common Shares in BHC Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Arax Advisory Partners holds $14,581,452 across 56 Drug Manufacturers - Specialty & Generic names. BHC ranks #46 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
24,261 | $4,088,948 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
6,216 | $3,368,015 | |
| 3 | VTRS |
Viatris Inc
|
83,877 | $1,331,966 | |
| 4 | HLN |
Haleon plc
|
81,966 | $764,742 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
21,768 | $737,499 | |
| 6 | ZTS |
Zoetis Inc.
|
9,047 | $650,117 | |
| 7 | TAK |
Takeda Pharmaceutical Co Ltd
|
39,210 | $628,536 | |
| 8 | IRWD |
Ironwood Pharmaceuticals Inc
|
126,966 | $534,526 |
All Filings in BHC
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $976 | 198 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $313 | 58 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $194 | 28 | Shares | Sole | 2026-02-13 | |
| 2022-06-30 | $1,463 | 175 | Shares | Sole | 2022-08-22 | |
| 2022-03-31 | $3,427 | 150 | Shares | Sole | 2022-05-12 | |
| No filing history on record for this holder in this stock. | ||||||